Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

被引：3
|
作者：
Zhou, C. [1 ]
Cheng, Y. [2 ]
He, Y. [3 ]
Li, W. [4 ]
Zhang, H. [5 ]
Zhou, Q. [6 ,7 ]
Wang, B. [8 ]
Liu, C. [9 ]
Ramalingam, S. [10 ]
Walding, A. [11 ]
Saggese, M. [11 ]
Wang, J. [12 ]
Fan, M. [12 ]
Wu, Y. [6 ,7 ]
机构：
[1] Tongji Univ, Pulm Hosp, Shanghai, Peoples R China
[2] Jilin Prov Canc Hosp, Thorac Oncol, Changchun, Jilin, Peoples R China
[3] Daping Hosp, Resp Dis, Chongqing, Peoples R China
[4] Jinlin Univ, Hosp 1, Changchun, Jilin, Peoples R China
[5] Forth Mil Med Univ, Tangdu Hosp, Oncol, Xian, Shaanxi, Peoples R China
[6] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[7] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[8] Yangzhou Univ, Subei PeopleS Hosp, Dept Oncol, Yangzhou, Jiangsu, Peoples R China
[9] Xinjiang Med Univ, Tumor Hosp, Urumqi, Peoples R China
[10] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA
[11] Astrazeneca, Global Med Dev, Cambridge, England
[12] Astrazeneca, Global Med Dev, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
osimertinib; China; NSCLC;
D O I：
10.1016/j.jtho.2018.08.669
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-112
引用
收藏
页码：S507 / S508
页数：2
相关论文
共 50 条
  • [41] Concurrent Chemotherapy and First-Generation EGFR-TKI as First-Line Treatment in Advanced Lung Adenocarcinoma Harboring EGFR Mutation
    Xu, Z.
    Hao, X.
    Lin, L.
    Li, J.
    Xing, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1111 - S1111
  • [42] Analysis of Efficacy and Safety of First Generation EGFR-TKI plus Apatinib in Treating Advanced NSCLC after EGFR-TKI Treatment Failure
    Feng, Y.
    Zhu, H.
    Hu, X.
    Liu, Y.
    Xing, P.
    Wang, H.
    Ji, X.
    Dai, Z.
    Shi, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S609 - S609
  • [43] Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC
    Tamura, Tomoki
    Hotta, Katsuyuki
    Gotoda, Hiroko
    Kato, Yuka
    Ichihara, Eiki
    Kubo, Toshio
    Tanimoto, Mltsune
    Kiura, Katsuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] The efficacy of chemotherapy in the advanced NSCLC patients who failed with the treatment of EGFR-TKI
    Zhou, S.
    Ren, S.
    Zhang, L.
    Sun, H.
    Zhou, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Real-World Data of Osimertinib in Patients with Metastatic EGFRm plus NSCLC who Progressed on First-Line EGFR TKIs
    Ma, J.
    Tan, S. H.
    Yin, D.
    Tran, A.
    Tan, D.
    Ang, M.
    Takano, A.
    Lim, K. H. T.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Tan, E.
    Lim, D. W.
    Ng, Q. S.
    Tan, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S627 - S628
  • [46] Overall Survival after Treatment with First-Line Osimertinib for EGFR-Mutant Advanced NSCLC in the US
    Sabari, J. K.
    Yu, H. A.
    Mahadevia, P.
    Liu, Y.
    Demirdjian, L.
    Sultan, A. A.
    Chen, Y. H.
    Wang, X.
    Passaro, A.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S619 - S620
  • [47] Adjusted Indirect Comparison of Osimertinib to Chemotherapy in NSCLC Patients with EGFRm T790M Who Progressed after EGFR-TKI
    Hoyle, C.
    Andersohn, F.
    Mitsudomi, T.
    Mok, T.
    Yang, J. C.
    Green, M.
    Mann, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1849 - S1850
  • [48] Tepotinib plus osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinib
    Tan, Daniel Shao-Weng
    Kim, Tae Min
    Guarneri, Valentina
    Voon, Pei Jye
    Lim, Boon Khaw
    Wislez, Marie
    Huang, Cheng
    Liam, Chong Kin
    Mazieres, Julien
    Tho, Lye Mun
    Hayashi, Hidetoshi
    Nhung, Nguyen
    Chia, Puey Ling
    De Marinis, Filippo
    Le, Xiuning
    Karachaliou, Niki
    Brutlach, Sabine
    Adrian, Svenja
    Ellers-Lenz, Barbara
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
    Imamura, Fumio
    Inoue, Takako
    Kunimasa, Kei
    Kubota, Aki
    Kuhara, Hanako
    Tamiya, Motohiro
    Nishino, Kazumi
    Kimura, Madoka
    Kuno, Kika
    Kawachi, Hayato
    Kumagai, Toru
    LUNG CANCER MANAGEMENT, 2020, 9 (02)
  • [50] First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
    Ji, W.
    Jiang, D.
    Zhang, J.
    Zhang, H.
    Wang, Q.
    Cang, S.
    Li, X.
    Tan, J.
    Xiang, Y.
    Li, X.
    Liu, A.
    Lu, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1693 - S1693
12345